Xtx Topco LTD 89bio, Inc. Transaction History

Xtx Topco LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$7.31 - $10.9 $233,759 - $348,560	31,978 New	31,978 $256,000
Q3 2023 Nov 13, 2023	BUY	$15.06 - $19.41 $218,851 - $282,066	14,532 New	14,532 $224,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $92,556 - $214,536	30,648 New	30,648 $177,000
Q2 2022 Aug 15, 2022	SELL	$2.09 - $4.02 $98,537 - $189,530	-47,147 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$3.45 - $14.99 $162,657 - $706,733	47,147 New	47,147 $178,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $369M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.